Newswire (Published: Thursday, December 20, 2018, 12:01:00 PM CST, Received: Thursday, December 20, 2018, 2:27:36 PM CST)

Word Count: 360

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on prostate cancer staging shows that PSMA-targeted PET/MRI performs equally as well as currently used predictive tools to determine the risk for advanced disease. The first-of-its-kind study, published in the December issue of The Journal of Nuclear Medicine, purports that whole-body imaging with 68Ga-PSMA-11 PET/MRI could be advantageous for physicians, as it offers information to guide treatment options for prostate cancer patients (see also Society of Nuclear Medicine and Molecular Imaging).

Accurate primary staging is imperative to develop individualized treatment strategies for those with prostate cancer. Currently, prediction tools--or nomograms--assess a variety of factors to determine risk of advanced disease: prostate-speci?c antigen value at diagnosis, Gleason score, and others. While these nomograms offer an estimate of probability, they do not specifically indicate the extent of disease, which can be obtained using molecular imaging.

To compare the performance 68Ga-PSMA-11 PET/MRI with clinical nomograms, researchers conducted a retrospective study including 73 patients. Each patient's risk for advanced disease was predicted using the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram, the Partin tables and 68Ga-PSMA-11 PET/MRI. The staging predictions were then compared with histopathologic results, specifically, the prevalence of lymph node metastases (LNM), extracapsular extension (ECE) and seminal vesicle invasion (SVI).

In each of the three advanced disease types analyzed (LNM, ECE and SVI), 68Ga-PSMA-11 PET/MRI resulted in an equivalent positivity rate compared with the MSKCC nomogram and the Partin tables. On a patient base, the sensitivity and specificity for 68Ga-PSMA-11 PET/MRI were also comparable to that of the other methodologies for the three disease types. Overall, a trend towards higher prediction of the final T and N stages on a patient base was noticed for PSMA-targeted molecular imaging.

"Our results showed that PSMA-targeted PET/MRI performed equally well to established clinical nomograms for preoperative staging in high-risk prostate cancer patients and provided additional information on tumor location" noted Andrei Gafita, MD. "Translated into a clinical setting, the use of this imaging technique for preoperative staging might support treatment planning that may lead to improved patient outcomes."

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Society of Nuclear Medicine and Molecular Imaging
Memorial Sloan-Kettering Cancer Center

Subjects

Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Radiology
                  Nuclear Medicine